Key Takeaways & Executive Findings
- •• • NLRP3 expression is significantly elevated in kidneys of active AAV patients, with concomitant increases in cleaved caspase-1 and N-terminal GSDMD in PBMCs, indicating systemic inflammasome activation and pyroptosis; this provides a mechanistic biomarker for disease activity and a potential target for therapeutic intervention in ANCA-associated vasculitis. • • MPO-ANCA IgG purified from new-onset AAV patients induces NLRP3 inflammasome activation and IL-1β production in LPS-primed macrophages in vitro, an effect linked to increased MPO expression and JNK MAPK signaling pathway activation; this establishes a direct causal role for autoantibodies in macrophage-driven inflammation. • • Immunofluorescence analysis demonstrates partial colocalization of CD206 and NLRP3 in AAV kidneys, and silencing of MRC1 (encoding CD206) reduces inflammasome activation induced by MPO-ANCA IgG; this identifies CD206 as a critical mediator of the pathogenic cascade, offering a novel target for disrupting M2 macrophage-associated inflammation. • • The study employed primary human macrophages and patient-derived MPO-ANCA IgG, with statistical significance set at p < 0.05 (as per standard in the field), ensuring clinical relevance; these findings lay the groundwork for developing targeted therapies that inhibit NLRP3 or CD206 to mitigate AAV progression and improve patient outcomes.
China Biomedical & Cell Therapy Radar
Get verified English translations, SEM micrographs & open-access PDF alerts from China's leading state key laboratories delivered to your inbox every Monday at 08:00 EST.
Abstract
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a life-threatening systemic autoimmune disease characterized by necrotizing small vessel vasculitis, with pauci-immune glomerulonephritis being the most severe manifestation. Macrophages, particularly CD206-positive M2 subsets, are central to AAV pathology, yet the mechanistic link between inflammasome activation and CD206 remains undefined. This study investigates NLRP3 inflammasome activity and pyroptosis in CD206+ macrophages exposed to myeloperoxidase (MPO)-ANCA immunoglobulin G (IgG). Newly diagnosed AAV patients and disease controls were recruited; renal NLRP3 and CD206 expression were assessed by immunofluorescence. MPO-ANCA IgG was purified from new-onset AAV patients and applied to lipopolysaccharide (LPS)-primed macrophages in vitro. Results demonstrate significantly elevated NLRP3 expression in active AAV kidneys, accompanied by increased cleaved caspase-1 and N-terminal gasdermin-D (GSDMD) in peripheral blood mononuclear cells (PBMCs). In vitro, MPO-ANCA IgG induces NLRP3 inflammasome activation and interleukin (IL)-1β production, associated with increased MPO expression and JNK signaling pathway activation. Immunofluorescence reveals partial colocalization of CD206 and NLRP3 in AAV kidneys. Silencing of MRC1, encoding CD206, reduces inflammasome activation induced by MPO-ANCA IgG. These findings establish that MPO-ANCA IgG contributes to NLRP3 inflammasome activation and macrophage pyroptosis, with CD206 playing a critical role. The study elucidates mechanisms underlying AAV inflammation and suggests potential therapeutic targets.
1. Introduction
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) remains a therapeutic challenge due to its relapsing-remitting course and limited treatment options that often carry substantial toxicity. Current standard-of-care immunosuppression, while effective in inducing remission, fails to prevent relapse in a significant proportion of patients and is associated with severe infectious complications. The mechanistic underpinnings of AAV, particularly the role of innate immune cells such as macrophages, have been inadequately addressed by existing therapies, which broadly suppress adaptive immunity rather than targeting specific inflammatory pathways.
The present study addresses this critical gap by investigating the NLRP3 inflammasome and pyroptosis in CD206+ macrophages exposed to MPO-ANCA IgG. By integrating clinical specimens from newly diagnosed AAV patients with in vitro mechanistic experiments, the authors delineate a pathway wherein MPO-ANCA IgG triggers NLRP3 activation, caspase-1 cleavage, and GSDMD-mediated pyroptosis, with CD206 playing a permissive role. This work provides a molecular framework for developing precision therapeutics that disrupt this axis, potentially offering safer and more effective strategies for managing AAV.
Loading authentic research manuscript (Pages 1–5)...
WEI Zhaonan, AN Xiaoning, XIE Yinyin, SHEN Yan, NI Liyan, XU Jing, WANG Yimei, SHEN Pingyan, SHI Hao, ZHANG Wen, CHEN Yongxi (2025). NLRP3 Inflammasome Activity and Pyroptosis Are Involved in CD206+ Macrophage Activation by MPO Anti-Neutrophil Cytoplasmic Antibodies. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2025080
Research & Educational Purpose Only: The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioDataare intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the specific mechanism by which MPO-ANCA IgG activates the NLRP3 inflammasome in macrophages, and how does this differ from canonical inflammasome activation?
MPO-ANCA IgG induces NLRP3 inflammasome activation in LPS-primed macrophages through a mechanism involving increased MPO expression and JNK MAPK signaling pathway activation. This differs from canonical activation, which typically requires two signals (priming and activation); here, MPO-ANCA IgG appears to provide both priming (via LPS) and activation signals, with MPO enzymatic activity being essential. The study demonstrates that silencing MRC1 (CD206) reduces inflammasome activation, indicating a non-canonical role for CD206 in facilitating this process.
What are the translational implications of CD206 and NLRP3 colocalization in AAV kidneys, and could this be exploited for targeted therapy?
Partial colocalization of CD206 and NLRP3 in AAV kidneys suggests that CD206+ macrophages are a major source of NLRP3 inflammasome activity. This offers a dual targeting opportunity: therapies could be designed to specifically inhibit NLRP3 in CD206+ cells or to block CD206-mediated signaling, thereby reducing IL-1β production and pyroptosis. Given that CD206 is a marker of M2 macrophages, which are typically anti-inflammatory, this finding challenges the paradigm and suggests that in AAV, CD206 may acquire a pro-inflammatory function.
What are the technical limitations of using patient-derived MPO-ANCA IgG in vitro, and how might these affect the reproducibility of the results?
Patient-derived MPO-ANCA IgG varies in titer, subclass, and glycosylation patterns, which can influence its pathogenic potential. The study used IgG purified from new-onset AAV patients, but the specific characteristics (e.g., MPO-ANCA titer, epitope specificity) were not fully detailed. This heterogeneity could affect reproducibility across different patient samples. Additionally, the in vitro system uses LPS-primed macrophages, which may not fully replicate the complex in vivo microenvironment. Future studies should standardize IgG preparations and validate findings in animal models.
How does the JNK signaling pathway contribute to NLRP3 inflammasome activation in this context, and could JNK inhibitors be repurposed for AAV therapy?
The study shows that MPO-ANCA IgG activates the JNK MAPK pathway, which is known to promote NLRP3 inflammasome assembly and IL-1β production. JNK inhibitors, such as SP600125, have been shown to reduce inflammasome activation in various models. However, systemic JNK inhibition may have broad immunosuppressive effects and toxicity. Targeted delivery to macrophages or development of specific inhibitors for the JNK isoform involved could mitigate these issues. Further preclinical studies are needed to assess efficacy and safety in AAV.
What is the clinical feasibility of targeting CD206 or NLRP3 in AAV patients, considering potential off-target effects and the need for chronic treatment?
Targeting CD206 or NLRP3 poses challenges: CD206 is expressed on various macrophage subsets and some endothelial cells, so systemic blockade could impair immune surveillance and tissue repair. NLRP3 inhibitors (e.g., MCC950) are in clinical trials for other inflammatory diseases but may increase infection risk. For AAV, intermittent or targeted delivery (e.g., nanoparticle-based) to inflamed kidneys could reduce systemic exposure. Biomarker-guided patient selection (e.g., those with high NLRP3 expression) would enhance risk-benefit. Long-term safety data are lacking, necessitating phase I trials.
Related Chinese Research & Cross-Citations
miR-199a-3p suppresses Vldlr expression to promote cardiomyocyte proliferation
The proliferative capacity of cardiomyocytes is limited in adult mammals, and replacing lost tissue following acute ischemic injury is challenging. Previous studies have demonstrated that miR-199a-3p can promote cardiomyocyte proliferation, but the exact mechanism by which this occurs remains unclear, although multiple targets of miR-199a-3p have been identified. We recently showed that very-low-density-lipoprotein receptor (Vldlr) inhibits cardiomyocyte proliferation, and in this study we aim to test whether Vldlr is a functional target gene of miR-199a-3p. 3′UTR reporter assays demonstrate that miR-199a-3p directly binds to the 3′UTR of Vldlr and inhibits its translation. Overexpressing Vldlr blunts the pro-proliferative effect of miR-199a-3p on cardiomyocytes, suggesting that Vldlr is indeed a functional target of miR-199a-3p. Mechanistically, Vldlr reduces S807/811 phosphorylation of RB1, and inhibiting CDK4/6 to prevent RB1 phosphorylation can block the pro-proliferative effect of both Vldlr knockdown and miR-199a-3p, suggesting that RB1 phosphorylation is required for the cardiomyocyte proliferation induced by miR-199a-3p and Vldlr knockdown. The findings of this study reveal Vldlr as a novel functional target of miR-199a-3p in cardiomyocytes and identify RB1 as a downstream effector of cardiomyocyte proliferation. The identification of the role of the miR-199a-3p-Vldlr-RB1 axis in cardiomyocyte proliferation may provide potential therapeutic targets for cardiac regenerative medicine.
A positive feedback loop between FOSB and miR-133b controls colon cancer cell proliferation
FOSB, a member of the FOS gene family, forms heterodimers with JUN family proteins to engage in diverse cellular processes. Its biological impacts vary among different types of tumors, yet its specific function in colon cancer (CC) remains ambiguous. In this study, quantitative real-time PCR (qRT-PCR) and immunohistochemistry (IHC) are applied to measure FOSB expression levels, followed by an analysis of the association between FOSB expression and patients’ clinical parameters. In vitro experiments are performed to assess cell proliferation, including growth rate, cell cycle distribution, and apoptosis. A subcutaneous xenograft model in nude mice is utilized to monitor tumor growth in vivo. Additionally, chromatin immunoprecipitation (ChIP) and luciferase reporter assays are conducted to dissect the interactions among FOSB, miR-133b, and POU2F1. The results indicate that FOSB expression is downregulated in CC tissues relative to normal controls. Overexpression of FOSB suppresses proliferation and promotes apoptosis in CC cells. Mechanistically, FOSB binds to the promoter region of miR-133b, enhancing its transcription and subsequently repressing POU2F1 expression. Notably, decreased POU2F1 expression also alleviates the transcriptional repression of the FOSB promoter region, establishing a FOSB-miR-133b-POU2F1 feedback loop that inhibits CC proliferation. In summary, our findings suggest that FOSB acts as a tumor suppressor gene in CC and may exert its inhibitory effects on CC growth via the FOSB-miR-133b-POU2F1 feedback loop.
Reduced expression of the PER2 protein contributes to β1-AA-induced cardiac autophagy rhythm disorders
Heart failure may be linked to fluctuations in the rhythm of autophagy in cardiomyocytes throughout the day. Circadian rhythms depend on the regulation of core biological clock proteins, with PER2 playing a crucial role. Our previous research confirmed that the presence of β1-adrenergic receptor autoantibodies (β1-AAs) could inhibit myocardial autophagy, leading to cell death and heart failure. However, it remains unclear whether β1-AA induces cardiac autophagy rhythm disorders by affecting PER2 expression. In this study, we find that β1-AA disrupts the autophagy rhythm in cardiomyocytes, which is primarily indicated by decreased expression of the autophagy marker protein LC3. β1-AA disrupts the rhythmic expression of the PER2 protein in myocardial cells, which is manifested mainly by a decrease in PER2 protein expression. Metoprolol is used to verify that the β1-adrenergic receptor contributes to the reduction in the Per2 protein caused by β1-AA. Knockdown of Per2 with lentivirus reduces the inhibition of LC3 expression caused by β1-AA, whereas overexpression of Per2 in cardiomyocytes using lentivirus significantly restores the β1-AA-induced decrease in LC3 expression. Moreover, mTORC1 activation is found to participate in β1-AA-induced autophagy inhibition in cardiomyocytes after pretreatment with the mTORC1 inhibitor rapamycin. Furthermore, the decreased expression of the PER2 protein caused by β1-AA disrupts the myocardial autophagy rhythm by promoting mTORC1 activation through lentiviruses that knock down or overexpress the Per2 gene. This study provides an experimental basis for the precise treatment of cardiovascular diseases from the perspective of biological rhythm.
A protein-RNA complex orchestrated by EMB1006, EMB1270, EMB976, and CFM2 facilitates clpP1 intron 2 splicing in Arabidopsis chloroplasts
In Arabidopsis, the PPR proteins EMB1006, EMB1270, and EMB976 are all essential for the splicing of plastid clpP1 intron 2 (clpP1.2), although each also targets other distinct RNAs. The precise mechanism underlying their co-ordinated action in clpP1.2 splicing remains unclear. In this study, RNA electrophoretic mobility shift assays, guided by PPR code prediction, confirm that EMB1006 specifically binds to a sequence near the 3′ end of clpP1 exon 2. Additionally, immunoprecipitation coupled with mass spectrometry reveals that EMB1006 forms a complex with EMB1270, EMB976, and CFM2. Direct interactions between EMB1006 and EMB1270 or CFM2 are further supported by yeast two-hybrid (Y2H) and semi-in vivo pull-down assays. However, no direct interactions between EMB976 and EMB1006, CFM2 or EMB1270 are detected by Y2H. Based on these findings and previous evidence that EMB1270 binds to clpP1 intron 2 and interacts with CFM2, we propose a model in which EMB1006 and EMB1270 bind to distinct sites on clpP1 pre-mRNA. Together with CFM2 and possible indirect association with EMB976, they assemble into a protein-RNA complex that facilitates the splicing of clpP1.2 in chloroplasts.
Tanshinones from Salvia miltiorrhiza alleviate ulcerative colitis via reprogramming the gut microbiota-metabolite axis
The anti-inflammatory properties of the traditional herb Salvia miltiorrhiza Bunge are well-established, yet its precise mechanism of action in ulcerative colitis (UC) remains unclear. Herein, we evaluate the therapeutic potential of four major tanshinones–tanshinone IIA (Tan IIA), miltirone, neocryptotanshinone, and dihydrotanshinone I–in a murine dextran sulfate sodium (DSS)-induced colitis model. Our results show that tanshinones effectively alleviate disease severity, suppress systemic and local inflammation, and restore intestinal barrier integrity. Integrated multi-omics analysis reveals that the therapeutic efficacy originates from a comprehensive reprogramming of the gut microbiota-metabolite axis. Specifically, tanshinones reverse colitis-associated dysbiosis and rectify metabolic disturbances in linoleic acid metabolism, bile acid biosynthesis, and amino acid utilization. Correlation network analysis identifies key functional modules linking beneficial microbes (e.g., Akkermansia) to anti-inflammatory lipid mediators and associating pathobionts (e.g., Desulfovibrio) with disrupted bile acid metabolism. Notably, supplementation with Akkermansia muciniphila synergizes with Tan IIA to amplify barrier restoration and metabolic normalization. Our findings establish that tanshinones ameliorate UC through microbiota-driven metabolic reprogramming, wherein the restructured microbial community actively shapes a therapeutic metabolic output. This work elucidates a metabolite-mediated mechanism of action and positions tanshinones as promising microbiome-targeting therapeutics for inflammatory bowel disease.
Distinct miR319a identified from Persicaria chinensis mediates cross-kingdom suppression of cervical cancer by targeting ITGA3
Persicaria chinensis, a well-known traditional Chinese medicinal herb that is both edible and medicinal, has been widely acknowledged for its therapeutic effects, such as anti-inflammatory, antioxidant, and antitumor activities. However, the role of miRNAs from this plant in the cross-kingdom regulation of human diseases has not been investigated. In this study, we analyze the miRNA expression profile of P. chinensis using high-throughput sequencing and identify a total of 673 miRNAs, including 422 novel miRNAs that are unique to this plant and 251 conserved miRNAs. Among the conserved miRNAs, pch-miR319a is found to be the most abundant. Moreover, food-oriented pch-miR319a accumulates in the uterus and tumors and exhibits a rich repertoire of target genes within cancer-related pathways, demonstrating significant cross-kingdom regulatory potential. Utilizing the dual-luciferase reporter gene assay, we demonstrate that pch-miR319a from P. chinensis targets the Itga3 gene, which is associated with cervical cancer progression. Overexpression of pch-miR319a significantly decreases the viability, migration, and induces apoptosis of HeLa cervical cancer cells in vitro. Moreover, in a syngeneic mouse tumor model of cervical cancer, treatment with pch-miR319a effectively inhibits tumor growth and downregulates the expressions of ITGA3 and the proliferation marker Ki-67. Our study highlights the potential of pch-miR319a from P. chinensis as a novel therapeutic agent for cervical cancer by targeting ITGA3 and provides new insights into the cross-kingdom regulatory mechanisms of plant miRNAs in human diseases.